Scholarlink

Background <p>Osteoarthritis (OA) is a common degenerative joint disease that lacks effective reparative treatment methods. Exosomes derived from synovial mesenchymal stem cells (SMSC) have emerged as a promising acellular therapeutic approach due to their roles in immune modulation and tissue regeneration. Metformin, a commonly used anti-diabetic drug, has been shown to possess anti-inflammatory properties and enhance stem cell functionality. This study aims to explore the therapeutic potential and underlying mechanisms of metformin-pretreated SMSC-derived exosomes (M-EVs) in OA treatment.</p> Methods <p>This study first conducted a retrospective analysis of clinical data from OA patients to evaluate the impact of metformin on joint damage. Subsequently, in vitro experiments were performed to investigate the effects of M-EVs on chondrocyte proliferation, apoptosis, migration, and extracellular matrix (ECM) metabolism. In addition, the in vivo efficacy of M-EVs was assessed in a DMM mouse model. Differentially expressed miRNAs were identified using miRNA arrays, and the role of the miR-1208/METTL3/NLRP3 signaling pathway in the therapeutic effects of M-EVs was further elucidated using luciferase reporter assays, m⁶A measurements, and Western blot analyses.</p> Results <p>Clinical data indicated that OA patients who had been on long-term metformin therapy exhibited less severe joint structural damage. In vitro experiments demonstrated that M-EVs, enriched in miR-1208, inhibited METTL3 expression and reduced m⁶A modification levels of NLRP3, thereby suppressing NLRP3 inflammasome activation and the release of pro-inflammatory factors. M-EVs significantly promoted chondrocyte proliferation and migration, reduced apoptosis, and improved ECM metabolism. Further animal studies confirmed that M-EVs effectively slowed OA progression, improved cartilage structure, and modulated the inflammatory microenvironment, with the therapeutic effect being dependent on the NLRP3 pathway.</p> Conclusion <p>Metformin-pretreated SMSCs enhance the anti-inflammatory and chondroprotective properties of their secreted exosomes, primarily through the miR-1208-mediated METTL3/NLRP3 signaling pathway. M-EVs offer an innovative, safe, and potentially translatable acellular therapeutic strategy for OA treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metformin-pretreated synovial mesenchymal stem cell-derived exosomes alleviate osteoarthritis via the miR-1208/METTL3/NLRP3 axis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月17日

查看全文
  • Shun-Bing Wang,
  • Yuan-Piao Ni,
  • Ruo Er-Li,
  • Xin Tu,
  • Yi Jiang,
  • Jian-Xiong Zheng,
  • Ao Duan,
  • Quan-Bo Zhang,
  • Yu-Feng Qing

摘要

Background

Osteoarthritis (OA) is a common degenerative joint disease that lacks effective reparative treatment methods. Exosomes derived from synovial mesenchymal stem cells (SMSC) have emerged as a promising acellular therapeutic approach due to their roles in immune modulation and tissue regeneration. Metformin, a commonly used anti-diabetic drug, has been shown to possess anti-inflammatory properties and enhance stem cell functionality. This study aims to explore the therapeutic potential and underlying mechanisms of metformin-pretreated SMSC-derived exosomes (M-EVs) in OA treatment.

Methods

This study first conducted a retrospective analysis of clinical data from OA patients to evaluate the impact of metformin on joint damage. Subsequently, in vitro experiments were performed to investigate the effects of M-EVs on chondrocyte proliferation, apoptosis, migration, and extracellular matrix (ECM) metabolism. In addition, the in vivo efficacy of M-EVs was assessed in a DMM mouse model. Differentially expressed miRNAs were identified using miRNA arrays, and the role of the miR-1208/METTL3/NLRP3 signaling pathway in the therapeutic effects of M-EVs was further elucidated using luciferase reporter assays, m⁶A measurements, and Western blot analyses.

Results

Clinical data indicated that OA patients who had been on long-term metformin therapy exhibited less severe joint structural damage. In vitro experiments demonstrated that M-EVs, enriched in miR-1208, inhibited METTL3 expression and reduced m⁶A modification levels of NLRP3, thereby suppressing NLRP3 inflammasome activation and the release of pro-inflammatory factors. M-EVs significantly promoted chondrocyte proliferation and migration, reduced apoptosis, and improved ECM metabolism. Further animal studies confirmed that M-EVs effectively slowed OA progression, improved cartilage structure, and modulated the inflammatory microenvironment, with the therapeutic effect being dependent on the NLRP3 pathway.

Conclusion

Metformin-pretreated SMSCs enhance the anti-inflammatory and chondroprotective properties of their secreted exosomes, primarily through the miR-1208-mediated METTL3/NLRP3 signaling pathway. M-EVs offer an innovative, safe, and potentially translatable acellular therapeutic strategy for OA treatment.

Graphical Abstract